Suppr超能文献

立体定向消融放疗(SABR)用于前列腺癌盆腔淋巴结寡转移复发

Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer.

作者信息

Lopez-Valcarcel Marta, Valcarcel Francisco J, Velasco Joaquin, Zapata Irma, Rodriguez Ruth, Cardona Jorge, Gil Beatriz, Cordoba Sofia, Benlloch Raquel, Hernandez Maria, Santana Sofia, Gomez Ricardo, De la Fuente Cristina, Garcia-Berrocal M Isabel, Regueiro Carlos, Romero Jesus

机构信息

Department of Radiation Oncology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

Medical Physics, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

出版信息

Rep Pract Oncol Radiother. 2024 Oct 3;29(4):445-453. doi: 10.5603/rpor.101528. eCollection 2024.

Abstract

BACKGROUND

This study evaluated the clinical outcomes of stereotactic ablative radiotherapy (SABR) in the treatment of oligometastatic pelvic node prostate cancer to delay androgen deprivation therapy (ADT).

MATERIALS AND METHODS

Pelvic lymph node metastases were identified by C-choline positron emission tomography (PET)-computed tomography (CT), and patients were not receiving ADT. SABR was administered using linear accelerators with intensity-modulated and image-guided radiotherapy, at a prescribed dose of 35 Gy in 5 fractions over 2 weeks. Response was assessed using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria, and prostate-specific antigen (PSA) levels were monitored post-SABR. Toxicity and quality of life were assessed by the Common Terminology Criteria for Adverse Events Toxicity (CTCAE) v.5.0 and European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires QLQ-C30/QLQ-PR25, respectively. Kaplan-Meier and T-test were used for statistical analysis.

RESULTS

Between June 2015 and November 2023, 56 patients with 85 lesions were treated at our institution. Median follow-up was 30 months [95% confidence interval (CI): 24-33.6]. Prostatectomy was the radical treatment in 85.7% of patients, and radiotherapy in 14.3%. Response rates were 67.1% for complete response, 27.4% for partial response, and 1.4% for stable disease. In-field progression was observed in only 3 lesions (3.5%). The median time to biochemical relapse post-SABR was 15 months (95% CI: 11.4-18.6). Three-year pelvic nodal and distant progression-free survival were 62.5% and 80%, respectively. There was a significant decrease in PSA levels after SABR compared to pretreatment levels (0.77 . 2.16 ng/mL respectively, p = 0.001). No grade ≥ 2 genitourinary or gastrointestinal toxicities. The median global health status score was 83.33 points at both time points analysed.

CONCLUSION

SABR can delay the ADT and provide excellent local control while preserving quality of life.

摘要

背景

本研究评估了立体定向消融放疗(SABR)治疗寡转移盆腔淋巴结前列腺癌以延迟雄激素剥夺治疗(ADT)的临床疗效。

材料与方法

通过C-胆碱正电子发射断层扫描(PET)-计算机断层扫描(CT)确定盆腔淋巴结转移,且患者未接受ADT。使用直线加速器进行SABR,采用调强放疗和图像引导放疗,规定剂量为35 Gy,分5次在2周内给予。使用实体瘤疗效评价标准(RECIST)v1.1标准评估反应,并在SABR后监测前列腺特异性抗原(PSA)水平。分别通过不良事件毒性通用术语标准(CTCAE)v.5.0和欧洲癌症研究与治疗组织(EORTC)生活质量问卷QLQ-C30/QLQ-PR25评估毒性和生活质量。采用Kaplan-Meier法和T检验进行统计分析。

结果

2015年6月至2023年11月期间,我院共治疗了56例患者的85个病灶。中位随访时间为30个月[95%置信区间(CI):24 - 33.6]。85.7%的患者接受了前列腺切除术作为根治性治疗,14.3%的患者接受了放疗。完全缓解率为67.1%,部分缓解率为27.4%,病情稳定率为1.4%。仅3个病灶(3.5%)观察到野内进展。SABR后生化复发的中位时间为15个月(95% CI:11.4 - 18.6)。三年盆腔淋巴结和远处无进展生存率分别为62.5%和80%。与治疗前水平相比,SABR后PSA水平显著降低(分别为0.77. 2.16 ng/mL,p = 零01)。无≥2级泌尿生殖系统或胃肠道毒性。在两个分析时间点,全球健康状况评分中位数均为83.33分。

结论

SABR可延迟ADT并提供良好的局部控制,同时保留生活质量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6166/11785391/0a0cec05ecb6/rpor-29-4-445f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验